Causal Associations Between Imaging-derived Phenotypes and Risk of Alzheimer’s Disease and Other Neurodegenerative Disorders: A Mendelian Randomization Study
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Accumulating observational studies have suggested associations between imaging-derived phenotypes (IDPs) and common neurodegenerative disorders, especially Alzheimer’s disease (AD). The goal of this study is to evaluate the causal associations between structural and functional IDPs and 4 neurodegenerative disorders, including AD, Parkinson’s disease (PD), Amyotrophic lateral sclerosis (ALS), and Multiple sclerosis (MS).
Methods
Bidirectional two-sample Mendelian randomization (MR) studies were conducted using summary statistics obtained from genome-wide association studies of 3909 IDPs from UK biobank and 4 neurodegenerative disorders.
Results
Forward MR analysis showed that volume of cerebral white matter in the left hemisphere was associated with increased risk of ALS (odds ratio [OR] = 1.15, 95% confidence interval [CI] = 1.09-1.22, P = 3.52 x 10 -6 ). In reverse MR analysis, we revealed genetically determined risk of AD and MS were associated with multiple IDPs (all P < 1.28 x 10 -5 [0.05/3909], 9 IDPs in AD and 4 IDPs in MS). For example, genetically determined risk of AD was causally associated with reduced volume of gray matter in right ventral striatum (OR = 0.95, 95% CI = 0.93-0.97, P = 4.68 x 10 -7 ) and lower rfMRI amplitudes in several nodes (ICA25 node 9, ICA25 node 8, and ICA100 node 11). Additionally, genetically determined risk of MS was causally associated with reduced volume in left putamen (OR = 0.97, 95% CI = 0.97-0.98, P = 4.47 x 10 -7 ) and increased orientation dispersion index in right hippocampus (OR = 1.03, 95% CI = 1.01-1.04, P = 2.02 x 10 -6 ).
Conclusions
Our study suggested plausible causal associations between risk of NDDs and brain IDPs. These findings might hold promise for identifying new disease mechanisms and developing novel preventative therapies for NDDs at the brain imaging levels.
